CN103690784B - The Chinese medicine composition for the treatment of Complicating with Hypentersion nephropathy and preparation method - Google Patents
The Chinese medicine composition for the treatment of Complicating with Hypentersion nephropathy and preparation method Download PDFInfo
- Publication number
- CN103690784B CN103690784B CN201310744647.0A CN201310744647A CN103690784B CN 103690784 B CN103690784 B CN 103690784B CN 201310744647 A CN201310744647 A CN 201310744647A CN 103690784 B CN103690784 B CN 103690784B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- parts
- medicine composition
- radix
- nephropathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 128
- 239000000203 mixture Substances 0.000 title claims abstract description 76
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 208000017169 kidney disease Diseases 0.000 title claims abstract description 13
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 9
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 9
- 235000008434 ginseng Nutrition 0.000 claims abstract description 9
- 239000009636 Huang Qi Substances 0.000 claims abstract description 7
- 241000208340 Araliaceae Species 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 241000628997 Flos Species 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 47
- 230000000694 effects Effects 0.000 abstract description 35
- 206010020772 Hypertension Diseases 0.000 abstract description 21
- 230000001225 therapeutic effect Effects 0.000 abstract description 10
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 229940127089 cytotoxic agent Drugs 0.000 abstract description 3
- 206010061623 Adverse drug reaction Diseases 0.000 abstract 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 abstract 1
- 231100000304 hepatotoxicity Toxicity 0.000 abstract 1
- 230000007056 liver toxicity Effects 0.000 abstract 1
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 54
- 210000004369 blood Anatomy 0.000 description 30
- 239000008280 blood Substances 0.000 description 30
- 229960005095 pioglitazone Drugs 0.000 description 27
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 25
- 239000008103 glucose Substances 0.000 description 25
- 241000700159 Rattus Species 0.000 description 21
- 210000004185 liver Anatomy 0.000 description 16
- 230000007812 deficiency Effects 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 210000003734 kidney Anatomy 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 238000003304 gavage Methods 0.000 description 12
- 210000002700 urine Anatomy 0.000 description 12
- 230000036772 blood pressure Effects 0.000 description 10
- 102000001554 Hemoglobins Human genes 0.000 description 9
- 108010054147 Hemoglobins Proteins 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000009467 reduction Effects 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 240000005373 Panax quinquefolius Species 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000001631 hypertensive effect Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 208000033809 Suppuration Diseases 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 206010037844 rash Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 208000008930 Low Back Pain Diseases 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 206010047531 Visual acuity reduced Diseases 0.000 description 3
- 208000031971 Yin Deficiency Diseases 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010010164 Hypertension complications Diseases 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028836 Neck pain Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000133570 Berberidaceae Species 0.000 description 1
- 206010006242 Breast enlargement Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 235000011305 Capsella bursa pastoris Nutrition 0.000 description 1
- 240000008867 Capsella bursa-pastoris Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 240000004528 Catalpa ovata Species 0.000 description 1
- 235000010005 Catalpa ovata Nutrition 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 244000040122 Elsholtzia pubescens Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 241001362411 Epimedium sagittatum Species 0.000 description 1
- 241001362415 Epimedium wushanense Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000208686 Eucommiaceae Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 244000283207 Indigofera tinctoria Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241001106041 Lycium Species 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010027627 Miliaria Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 241000313287 Oncopera intricata Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- JMFSHKGXVSAJFY-UHFFFAOYSA-N Saponaretin Natural products OCC(O)C1OC(Oc2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C1O JMFSHKGXVSAJFY-UHFFFAOYSA-N 0.000 description 1
- 241000304447 Sempervivum tectorum Species 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- MOZJVOCOKZLBQB-UHFFFAOYSA-N Vitexin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C(O)C1O MOZJVOCOKZLBQB-UHFFFAOYSA-N 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical group CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 210000003017 ductus arteriosus Anatomy 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- -1 sublimed preparation Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- SGEWCQFRYRRZDC-VPRICQMDSA-N vitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O SGEWCQFRYRRZDC-VPRICQMDSA-N 0.000 description 1
- PZKISQRTNNHUGF-UHFFFAOYSA-N vitexine Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O PZKISQRTNNHUGF-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to medical art, relate to a kind of Chinese medicine composition and preparation method thereof, particularly a kind ofly treat Chinese medicine composition of Complicating with Hypentersion nephropathy and preparation method thereof.Chemotherapeutic agent liver toxicity for current Complicating with Hypentersion nephropathy is larger, the prior art of unsatisfactory curative effect is not enough, the Chinese medicine composition that a kind for the treatment of or diabetes and nephropathy preventing complicated hypertension nephropathy are provided of the present invention, it comprises following component: Herba Epimedii 10-50 part, Cortex Eucommiae 10-20 part, Radix Rehmanniae 5-20 part, Rhizoma Polygonati 5-15 part, Radix Puerariae 5-15 part, Radix Ginseng 1-10 part, Fructus Lycii 5-15 part, Radix Astragali 9-15 part, Fructus Ligustri Lucidi 9-15 part, Radix Platycodonis 5-15 part, Radix Ophiopogonis 1.5-9 part, Rhizoma Pinelliae 5.5-15 part.This Chinese medicine composition all has good therapeutic effect in treatment or diabetes and nephropathy preventing complicated hypertension nephropathy, and drug side effect is low, has significant clinical generalization value.
Description
Technical field
The invention belongs to medical art, be specifically related to a kind ofly treat Chinese medicine composition of Complicating with Hypentersion nephropathy and preparation method thereof.
Background technology
Diabetes are a kind of incretion metabolism diseases, be due to insulin in body relatively or definitely not enough and carbohydate metabolism that is that cause is disorderly, cause the disease of the water and electrolyte metabolism disorder of sugar, protein, fat and secondary.Diabetes divide two types clinically: insulin dependent diabetes mellitus (IDDM) (i.e. type i diabetes), non-insulin-dependent diabetes mellitus (i.e. type ii diabetes).Wherein, it is very high that type ii diabetes sends out rate, accounts for about 90% of onset diabetes number.The harm of diabetes is mainly from complication, and its incidence rate is very high, result in high fatality rate and high disability rate.Research shows, within after onset diabetes 10 years, has the patient of 30%-40%, to I haven't seen you for ages, a kind of complication occurs.The nephropathy that common diabetic complication has diabetes to cause, eyes pathological changes, nervous system lesion, cardiovascular pathological changes, fatty liver etc.
World Health Organization (WHO) announces recently, nineteen ninety-five, whole world diabetics was only about 3,000 ten thousand people, and to 1997 oneself increase to 1.35 hundred million, predict according to authoritative sources, to 2.4 hundred million be reached by 2010, by 2025,3.3 hundred million people will be had to be diagnosed as diabetes, and mortality rate is only second to malignant tumor and cardiovascular diseases, it is the third-largest disease jeopardizing human life's health.Along with the raising of living standards of the people, the incidence rate of China's diabetics and mortality rate are also increasing severely year by year.From the finding of China each department distribution, the eighties China's diabetics sickness rate less than 1%, rose to 2.65% by 1997, and more increase rapidly with the speed of annual 0.1% in recent years, formed a diseased colonies that can not be ignored.
Diabetes are also called diabetes, and the traditional Chinese medical science thinks that its origin cause of formation is many due to surfeit delicious food, eating and drinking without temperance, congenital defect, and ferritic the moon loses, or gives up completely to natural impulse, disorder of emotion, or impairment caused by overstrain excessively causes cloudy body fluid deficiency consumption, scorching, more damage cloudy Tianjin, the two reciprocal causation.Liver take blood as body, and with gas for, liver controlling conveyance and dispersion, regulate human physiological functions, irritability catharsis, then happy, QI and blood is gentle, if depressed emotion or rage impairing liver, strongly fragrant and fire-transformation, then liquid is hindered in Tianjin of burning, and viscera function is disorderly, thus causes diabetes.Prevent and treat diabetes key to be to keep the control of blood glucose steadily and to its complication.The method controlling blood glucose is not simple treatment, it not more simple Drug therapy, but according to the World Health Organization (WHO), the five-term measure controlling diabetes is proposed, namely diet control, exercise therapy, Drug therapy, diabetes education, blood sugar monitoring carry out integrated control.Wherein, Drug therapy is the key of control blood glucose.Although chemical sugar-lowering medicine can control hyperglycemia to a certain extent, due to the toxic and side effects of itself, serious infringement is caused to the organ such as liver, kidney, the heart, brain of human body, increases the weight of the development of complication.TCM treatment of diabetes is then particular about whole body conditioning, giving consideration to both the incidental and fundamental, is its advantage but often takes effect slow.
Hypertension is one of modal cardiovascular disease, as closely related in coronary heart disease, cerebrovascular disease etc. with the principal disease of human death again, although the sickness rate of China's hypertension is high not as western countries, but in raising trend year by year, along with the deterioration with environment that improves constantly of people's living standard, suffer from hypertension, hyperlipidemia, hypercholesterolemia class cardiovascular patient also in continuous increase, according to interrelated data report by the end of the year in 2003, China hyperpietic has reached 1.5 hundred million people, and increases with the speed of annual 5000000 people.The research of hypertension from pathogeny so that clinical prevention is all attached great importance in countries in the world.Hypertension major determinant human vas.It can impel ductus arteriosus wall hardening, and if tube chamber stenosis is narrow hypertension complication with diabetes, then can be accelerated, increase the weight of vascular lesion, the state of an illness is worsened rapidly namely at ordinary times said " arteriosclerosis ", should active treatment.
Make a general survey of the research direction of world's new drug, the eighties mainly researched and developed single chemicals and preparation thereof in the past, and start after the eighties to develop biotechnology and natural medicinal plants, drug research direction is tending towards multiformity.In conjunction with modern Chinese medicine theory of development, from improving curative effect of medication, reducing the angle of side effect, through carrying out to Chinese medicine ingredients the preparation that screening is extracted and/or compatibility is obtained, its side effect is little, and safety is high, has the advantage that chemical synthetic drug can not be compared.
Summary of the invention
Large in order to overcome existing diabetes chemotherapeutic agent toxic and side effects, the prior art that treating diabetes effect is difficult to continue is not enough, the invention provides a kind of Chinese medicine composition for the treatment of diabetes, this Chinese medicine composition good effect, side effect is little, and it obtains primarily of following raw material: Herba Epimedii 10-50 part, Cortex Eucommiae 10-20 part, Radix Rehmanniae 5-20 part, Rhizoma Polygonati 5-15 part, Radix Puerariae 5-15 part, Radix Ginseng 1-10 part, Fructus Lycii 5-15 part, Radix Astragali 9-15 part, Fructus Ligustri Lucidi 9-15 part, Radix Platycodonis 5-15 part, Radix Ophiopogonis 1.5-9 part, Rhizoma Pinelliae 5.5-15 part.
Herba Epimedii Herba Epimedii is the stem and leaf of Berberidaceae plant Herba Epimedii, frontal lobe Herba Epimedii, Epimedium sagittatum, Epimedium wushanense, Herba Epimedii, E. Pubescens etc.There is kidney invigorating and YANG supporting; Expelling wind and removing dampness; Strong muscle key bone effect, function cures mainly: impotence and seminal emission; Cold caused by deficiency is sterile; Frequent micturition loses Chu; Dyspnea and cough due to deficiency of the kidney; Soreness of the waist and knees; Rheumatic arthralgia; Hemiplegia; Extremity are meciless waits disease.
The Cortex Eucommiae is the dry bark of the Eucommiaceae plant Cortex Eucommiae, is Chinese famous and precious tonic herb.Tool invigorating the liver and kidney, bone and muscle strengthening, blood pressure lowering, many effects such as antiabortive.Suitable hyperpietic, habitual abortion women, poliomyelitis sequela patient, deficiency of kidney-QI person.The careful clothes of hyperactivity of fire caused by deficiency of YIN person.The Cortex Eucommiae joins Radix Achyranthis Bidentatae, and the power of invigorating the liver and kidney and bone and muscle strengthening strengthens, the disease such as be usually used in the lumbago and skelalgia for the treatment of the liver kidney deficiency and two foots are unable.The Cortex Eucommiae joins Cortex Acanthopancis, not only strong muscles and bones but also wind-damp dispelling, is the medicine pair of reinforcing and reducing concurrently, and Suitable therapeutic Liver and kidney two is empty, the lumbago and skelalgia that rheumatism invades muscles and bones and causes, sufficient knee joint soreness, articular instability, the diseases such as two weakness of the lower extremitiess.The Cortex Eucommiae joins Radix Dipsaci, function invigorating the liver and kidney, sharp waist knee joint, and Gu Chong appoints, and is usually used in all diseases caused by deficiency of the liver and kindey.The Cortex Eucommiae joins Fructus Psoraleae, and warming and recuperating the kidney-YANG power increases, hold concurrently spleen reinforcing, liver, both puckery lower unit, Gu Chong appoints again, is usually used in insufficiency of kidney-YANG, the sexual impotence of below element deficiency and cold, the spermatorrhea enuresis of chills and pain of the waist and kness and instability of kidney-QI, also can be used for the soreness of the waist and knees of deficiency of the liver and kindey, and frequent fetal movement and deficiency of spleen-YANG and kidneyYANG such as to be had loose bowels the disease.
The Radix Rehmanniae, is also Radix Rehmanniae, Scrophulariaceae herbaceos perennial.Sweet-bitter flavor, cold nature, GUIXIN, liver, kidney channel.Matter profit is fallen and is let out, and has the nourishing YIN to relieve dryness effect of promoting the production of body fluid.Rhizoma Polygonati is used as medicine with rhizome.There is boosting qi and nourishing yin, spleen invigorating, lung moistening, kidney benefiting functions.Be used for the treatment of weakness of the spleen and stomach, fatigue and asthenia, xerostomia lack of appetite, deficiency of the lung cough caused by dryness, asthenia of essence and blood, interior-heat such as to be quenched one's thirst the disease.
Radix Puerariae is the dry root of legume pueraria lobata.Having induces sweat brings down a fever, and promotes the production of body fluid, rash, effect of yang invigorating antidiarrheal.For fever caused by exogenous pathogens headache, hypertension neck pain, thirsty, quench one's thirst, measles without adequate eruption, hematodiarrhoea, to have loose bowels.Radix Puerariae flavone has cancer-resisting and estrogen-like effects, can promote women's breast enlargement, skin care, especially to middle-aged women and the effect of menopausal women face-nourishing health-care obvious.The cardiovascular and cerebrovascular vessel patients such as hypertension, hyperlipidemia, hyperglycemia and migraine, climacteric women, easily get angry crowd's (comprising anemia of pregnant woman and baby), normal phase alcohol user (reducing ethanol to hepatic effects), women grow appearance skin care, middle-aged and elderly people daily diet conditioning etc.Powder of Radix Puerariae sweet in the mouth cool in nature is pungent, and having induces sweat brings down a fever, and promotes the production of body fluid, the several functions such as rash, yang invigorating antidiarrheal, can control fever caused by exogenous pathogens headache, hypertension neck pain, thirsty, quench one's thirst, measles without adequate eruption, heat rash, the various diseases such as to have loose bowels.
The medical value of Radix Ginseng is high, just thinks in Shennong's Herbal, Radix Ginseng has " tonifying five ZANG-organs, peace spirit, determine soul, spasmolytic is throbbed with fear, except pathogen, the happy Fructus Alpiniae Oxyphyllae of improving eyesight " effect.Pharmacological research shows that Radix Ginseng all has Normal Canine and alloxan diabetes dog and reduces blood glucose effect, has obvious hypoglycemic activity to alloxan diabetes Mus.Radix Ginseng total saponins can obviously suppress the hyperglycemia of alloxan diabetes Mus and after drug withdrawal, its effect still can maintain 1-2 week.Clinical research shows, Radix Ginseng treatment diabetes not only can improve general symptom as weak, thirsty, weak etc., and can reduce blood glucose and glucose in urine.Be applicable to light, middle diabetes mellitus type, Chinese medical discrimination suffered from a deficiency of the kidney, gas deficiency of YIN person better efficacy, the deficiency of YIN scorching person should not take.
Fructus Lycii (formal name used at school: Lycium chinense) is the multi-branched shrub plant of Solanaceae Lycium, and high 0.5-1 rice, can reach more than 2 meters during cultivation.All there is distribution both at home and abroad.Fructus Lycii whole body is precious, and bright Li Shizhen (1518-1593 A.D.) Compendium of Material Medica is recorded: " spring adopts Folium Lycii, name sky essence grass; Summer picks flowers, name Sempervivum tectorum; Qiu Caizi, name Fructus Lycii; Dong Caigen, name Cortex Lycii ".Fructus Lycii tender leaf also known as Fructus Lycii head, edible or make Fructus Lycii tea.Modern study, Fructus Lycii has reduction blood glucose, lipotropy, and can antiatherogenic effect.
The Radix Astragali has another name called Radix Astragali, and Chinese medicine astragalus is the dry root of leguminous plant Radix Astagali or Radix Astragali.There is invigorating QI to consolidate the body surface resistance, inducing diuresis to remove edema, expelling pus and toxin by strengthening QI, effect of expelling pus and promoting granulation.Have enhancing human body immunity function, protect the liver, diuresis, defying age, anti-stress, blood pressure lowering and antibacterial action more widely.But table excess pathogen is contained, retention of dampness due to stagnation of QI, and food stagnation is stagnated, carbuncle from the beginning of or the excess syndrome such as pyretic toxicity Shang Sheng after bursting, and hyperactivity of YANG due to deficiency of YIN person, must prohibit clothes.
The dry mature fruit of Fructus Ligustri Lucidi Oleaceae plants Fructus Ligustri Lucidi.Another name: Fructus Ligustri Lucidi reality, Fructus Ilicis Purpureae, quick-fried lattice flea, white beeswax tree, Mus Chinese catalpa.There is nourishing the liver and kidney, effect of improving eyesight black hair.For vertigo and tinnitus, soreness of the waist and knees, early whitening of beard and hair, poor vision.For the poor vision of the hepatic and renal YIN deficiency, visual deterioration, early whitening of beard and hair, soreness of waist tinnitus and fever due to yin deficiency etc.This product energy tonifying liver kidney yin, but the efficacy of a drug is gentle, slowly must get effect.Control poor vision, often join Radix Rehmanniae Preparata, Semen Cuscutae, Fructus Lycii is equal to use, controls early whitening of beard and hair, often joins Herba Ecliptae, and Fructus Mori are equal to use, controls fever due to yin deficiency, often joins Cortex Lycii, and Radix Rehmanniae is equivalent to be used.
Radix Platycodonis is the dry root of Campanulaceae Radix Platycodonis.Radix Platycodonis has lung qi dispersing to eliminate the phlegm, effect of sore-throat relieving evacuation of pus.Radix Platycodonis is called: symbol Hu, BAIYAO, profit are as, stalk grass, Lu Ru, Fang Tu, shepherd's purse century, Radix Platycodi, RADIX PLATYCODI, greatly medicine, Radix Sonchi Oleracei, and Radix Platycodonis cures mainly: cough with copious phlegm, and expectoration is not well, and chest and diaphragm painful abdominal mass is vexed, laryngopharynx swelling and pain, and lung abscess coughs vomiting bloody pus.
Radix Ophiopogonis, having another name called Radix Ophiopogonis, is Liliaceae Ophiopogon plant.Radix Ophiopogonis is used as medicine with tuber.Nature,taste and action: sweet, micro-hardship, cool, Yin-nourishing and body fluid promoting, nourishing the lung to arrest cough, clear away heart-fire relieving restlessness.Cure mainly consumption of body fluid caused by febrile disease, vexed, thirsty, dry pharynx lung-heat, cough, pulmonary tuberculosis.The Rhizoma Pinelliae cry again water beautiful, literary composition and aunt, evil field, show aunt, the sheep eye Rhizoma Pinelliae, the pearl Rhizoma Pinelliae, numb taro fruit, three step jumpings, general stone, old shaven head, crow head, Fructus Crotonis, be not in the mood for dish root, corbie eye, Thunder God, Canis familiaris L. Fructus Colocasiae Esculentae.Its toxicity is that Herb is poisonous, and tuber toxicity is larger.The Rhizoma Pinelliae has drying dampness to eliminate phlegm; Stopping nausea and vomiting by lowering the adverse flow of QI; Effect of dissolving lump and resolving mass.
The parts by weight of the present invention to above-mentioned all taste Chinese medicine carry out preferably, preferred condition be after drug matching uses medicine to the enhancing of Complicating with Hypentersion treatment of kidney disease effect.As a preferred embodiment of the present invention, Chinese medicine composition of the present invention obtains primarily of the raw material of following weight portion: Herba Epimedii 30 parts, the Cortex Eucommiae 15 parts, 15 parts, the Radix Rehmanniae, Rhizoma Polygonati 10 parts, Radix Puerariae 12 parts, Radix Ginseng 7 parts, Fructus Lycii 12 parts, the Radix Astragali 13 parts, Fructus Ligustri Lucidi 14 parts, Radix Platycodonis 10 parts, Radix Ophiopogonis 5 parts, the Rhizoma Pinelliae 11 parts.
Preferably, Chinese medicine composition of the present invention also contains Rhizoma Chuanxiong 7 parts further, Fructus Crataegi 5 parts, 9 parts, Flos Carthami.The pungent temperature of Rhizoma Chuanxiong is fragrant dry, walks and does not keep, can go loose, and the up mountain peak that reaches is pushed up; Enter blood system again, descendingly reach the sea of blood.Blood circulation promoting and blood stasis dispelling effect is extensive, the suitable various disease of stagnation of blood stasis; Wind-expelling pain-stopping, effectiveness is excellent, can control the diseases such as wind syndrome of head headache, rheumatic arthralgia.Fructus Crataegi does medicinal with fruit, have the function of promoting digestion and invigorating the stomach, activating blood circulation to dissipate blood stasis, convergence dysentery relieving.To meat amass phlegm retention, feeling of fullness acid regurgitation, dysentery hemorrhoidal hamorrhage, lumbago hernia, puerperal after-pains, lochiorrhea, children's breast food stagnate etc., all effective in cure.Hyperchlorhydria, peptic ulcer and dental caries person, dyspepsia person, cardiovascular patient, cancer patient, enteritis patient and avoiding during taking tonic takes.The careful clothes of weakness of the spleen and stomach person.Fructus Crataegi has important medical value, since ancient times, just becomes the good medicine of spleen benefiting and stimulating the appetite, relieving dyspepsia, phlegm reduction of blood circulation promoting.Fructus Crataegi, containing materials such as saccharide, protein, fat, vitamin C, carotene, starch, malic acid, citric acid, calcium and ferrum, has the effects such as blood fat reducing, blood pressure, heart tonifying and arrhythmia.Flavone compound vitexin in Fructus Crataegi, be the medicine that a kind of antitumaous effect is stronger, Fructus Crataegi extract all has certain inhibitory action to cancerous cell tumor growth, propagation and infiltration metastasis.Flos Carthami, also known as red indigo plant flower, thorn Flos Carthami, Flos Carthami, has promoting blood circulation to restore menstrual flow, the effect of silt pain relieving of dispelling.Cure mainly dysmenorrhea amenorrhea, traumatic injury, joint aches, coronary heart disease.Fruit medicine, effect with spend identical.Be not taken by pregnant women, have bleeding tendency person to be cautious use of.Seed oil content is higher than Semen sojae atricolor, and wherein linoleic acid content is up to 84%, has blood fat reducing and serum cholesterol, and the effect of atherosclerosis occupies the hat of edible oil.Pharmaceutically safflower oil is widely used as the stabilizing agent of antioxidant and vitamin A, D.
In order to express Chinese medicine composition of the present invention better, Chinese medicine composition of the present invention can be prepared into dosage form conventional clinically.Such as, the preparation such as powderous preparations, powder, pill, sublimed preparation, unguentum, granule, oral liquid, syrup, tablet, capsule.Preferably, Chinese medicine composition of the present invention conveniently preparation technology be prepared into powder, water preparation, tablet or capsule.
Present invention also offers a kind of preparation method of Chinese medicine composition described above, it mainly comprises following step: get traditional Chinese medicinal material raw materials in proportion and be broken into coarse powder, doubly add according to the 4-9 of coarse powder gross weight the alcoholic solution that volumetric concentration is 40%-95%, reflux, extract, three times, return time is 2-5h, filter, filtrate recycling ethanol, cold filtration, washes with water, namely obtain Chinese medical concrete after drying, obtain Chinese medicine composition according to different dosage form.Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically, as tablet, capsule etc. in this preparation method.
The present invention also asks to protect the purposes of above-mentioned Chinese medicine composition in preparation treatment diabetes medicament.Test examples 19 of the present invention shows, significant synergism is there is in Chinese medicine composition Chinese medicine composition of the present invention in treating diabetes, it is compared with positive control drug pioglitazone, not only fasting glucose and 2h-plasma glucose can be significantly reduced, and glycolated hemoglobin and urine micro protein can be significantly reduced.This shows that Chinese medicine composition of the present invention significantly can not only improve the symptom of diabetes in treating diabetes, can also delay the development of diabetes, reduces the generation of complication.
In a word, the present invention compared with prior art has following advantage:
1) compared with positive control drug pioglitazone, pharmaceutical composition Chinese medicine composition of the present invention is not only more remarkable in reduction fasting glucose and 2h-plasma glucose, and also significantly positive drug is better than in reduction glycolated hemoglobin and urine micro protein, this shows that the present composition has significant synergism in treating diabetes, significantly can not only improve the symptom of diabetes, the development of diabetes can also be delayed, reduce the generation of complication.
2) compared with the chemotherapeutic agent of Current therapeutic diabetes, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, untoward reaction and side effect significantly reduce, and Chinese medicine composition effect of the present invention is comprehensive, medication effect is better, significantly improve the compliance of diabetics, and improve the quality of life of patient.
3) existing Remedies for diabetes diabetes mellitus therapeutic effect still can, but all occur obvious drug resistance problem along with the prolongation for the treatment of time, the therapeutic effect of diabetes declines.Containing multi-medicament component in Chinese medicine composition of the present invention, action target spot is numerous, efficiently solves the Commpensation And Adaptation of Remedies for diabetes, and it does not decline because treatment time extends to the therapeutic effect of diabetes.
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, the present invention is not limited only to following examples.Within the scope of the invention or not departing from content of the present invention, spirit and scope, the change carried out the present invention, combination or replacement, be apparent for a person skilled in the art, and be included within the scope of the present invention.
part I Chinese medicinal composition preparation of the present invention, preparation and using method thereof
embodiment 1-6 Chinese medicine composition composition powders
table 1 Chinese medicine composition composition powders of the present invention prescription
Embodiment 1 preparation method: get each medical material in compositions, conveniently technique grinds to form powdery, cross 100 mesh sieves, little fire drying is for subsequent use, obtains powder.During use, directly take after mixing it with water with after water dissolution.Embodiment 2-6 preparation method is with embodiment 1.
embodiment 7-12 Chinese medicine composition water preparation
table 2 Chinese medicine composition water preparation of the present invention prescription
Embodiment 7 preparation method: get each medical material in prescription, conveniently decocting for Chinese herbal medicine technological operation, filtering medicinal residues and get final product.When this water preparation (or claiming decoction) is for treating diabetes, daily 2-3 time.Embodiment 8-12 preparation method and using method are with embodiment 7.
embodiment 13-18 Chinese medicine composition tablet/capsule of the present invention
table 3 Chinese medicine composition tablet of the present invention/capsule prescription
Embodiment 13 preparation technology: each traditional Chinese medicine powder getting recipe quantity is broken into coarse powder, adds according to 5 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 80%, reflux, extract, three times, the each 3h of return time, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; By Chinese medical concrete drying, pulverize and make dried cream powder, add customary adjuvant components utilising prior art and be prepared into tablet or capsule.Embodiment 14-18 preparation technology is with embodiment 13.
part II Chinese medicine composition pharmacodynamic study of the present invention
embodiment 19: Chinese medicine composition of the present invention causes the therapeutical effect of diabetes rat model to streptozotocin
1, experimental diabetic animal models preparation
Body weight 160-180gWistar rat, male and female half and half, first feed with high-sugar-fat-diet (albumen selects matter 5%, carbohydrate 60%, and wherein sucrose is 30%, fatty 32%, and wherein refining Adeps Sus domestica is 30%) after 4 weeks, Rat Fast 18h.Lumbar injection 0.6% streptozotocin (STZ) 30mg/kg, STZ are dissolved in pH4.0, and in 0.1mol/L citric acid-sodium citrate buffer, each dose is finished in 10min.Blank group rats by intraperitoneal injection equal-volume citric acid-sodium citrate buffer, normally raises.Within 5 days, dock afterwards and get blood survey whole blood sugar, with blood glucose value horizontal > 10.0mmol/L person for modeling success.
2, experiment grouping and administration
Modeling success rat is divided into model control group according to blood sugar level, pioglitazone group, Chinese medicine composition A group, Chinese medicine composition B group, Chinese medicine composition C group, Chinese medicine composition D group totally 6 groups at random, often organizes 10.Each group gives following medicine respectively:
Model control group: gavage gives equal-volume normal saline;
Pioglitazone group: gavage gives pioglitazone 2.5mg/kgd;
Chinese medicine A group: it is the Chinese medicine composition composition powders of 1g/kgd that gavage gives crude drug amount prepared by embodiment 1;
Chinese medicine B group: it is the Chinese medicine composition water preparation of 3g/kgd that gavage gives crude drug amount prepared by embodiment 7;
Chinese medicine C group: the crude drug amount that gavage gives embodiment 13 preparation is the Chinese medicine composition tablet of 3g/kgd;
Chinese medicine D group: the crude drug amount that gavage gives embodiment 18 preparation is the agent of 10g/kgd Chinese medicinal composition capsules.
Above-mentioned administration group is administered once every day, continuous 10 weeks.Blood sampling measures fasting glucose, feed rear 2h blood glucose, glycolated hemoglobin (HbAlc) and urine micro protein.
3, index determining
The mensuration of 3.1 blood glucose: after modeling success rat random packet, according to dosage gastric infusion, continuous 10 weeks, normally raises.All rats detect fasting glucose (FBG), 2h blood glucose (PBG) after feed respectively at getting weekly tail vein in 4 weeks before treatment and after treatment.The blood sample of taking-up is put into protein precipitant, after room temperature places 7min, centrifugal 5min(3000r/min), get supernatant, survey whole blood sugar with glucose oxidase method.
The mensuration of 3.2 glycolated hemoglobins (HbAlc): (grouping, the same blood sugar detection of administration) fasting 12h after last administration, etherization, eye socket gets blood, measures HbAlc by description in test kit.
The mensuration of microalbumin in 3.3 urine:
Reagent: a, 10%(v/v) glacial acetic acid solution (PH2.8);
B, 0.303mol/L glycine-glacial acetic acid buffer (PH3.0): take 22.72g glycine, be diluted to 1000ml with 10% glacial acetic acid solution, add NaN
3100mg, Room-temperature seal Absorbable organic halogens 1 year;
C, bromophenol blue (1.924mmol/L) stock solution: accurately take 257,36mgBPB, molten to 200ml with dehydrated alcohol, 4 DEG C of refrigerator Absorbable organic halogens 1 year;
D, bromophenol blue (0.231mmol/L) developer: get 60mlBPB stock solution, add 2.5mlTriton X-100, be diluted to 500ml with glycine-glacial acetic acid buffer, Room-temperature seal can preserve 1 year.
The collection of specimen and detection: in the 1st, 3,7 and 10 week rat is put in metabolic cage respectively and raises, collect 12 hours overnight urine, accurate recording urine volume.Get 4ml, after sodium azide process, centrifugal (2000r/min) 10min, gets supernatant and puts-20 DEG C of Refrigerator store urinaryalbumin to be measured.The albumin standards 400 getting respective concentration, in the cup of correspondence, respectively adds 200 developers, and mixing (preventing bubble), with ultraviolet spectrophotometer, measures absorbance A under 600nm.
4, experimental result and discussion
The impact of 4.1 Chinese medicine composition blood glucose in diabetic rats of the present invention
Table 1 Chinese medicine composition of the present invention is on the impact of 2h blood glucose after diabetes rat fasting glucose and feed
*compare with model group, P < 0.05,
*compare with model group, P < 0.01;
#compare with pioglitazone group, P < 0.05,
##compare with pioglitazone group, P < 0.01.
Above-mentioned experimental result shows, Chinese medicine composition compared with pioglitazone reduction fasting glucose and 2h-plasma glucose in effect better.Be embodied in:
1) no matter be fasting glucose or 2h-plasma glucose, pioglitazone group and Chinese medicine A, B, C, D group have significant difference with model group, and Chinese drug-treated group compares with model group pole significant difference;
2) compared with pioglitazone group, each group of Chinese medicine has pole significant difference in reduction fasting glucose;
3) compared with pioglitazone group, Chinese medicine A, B, C group is having significant difference in reduction 2h-plasma glucose, and Chinese medicine D pioglitazone group has compared significant difference.
4.2 Chinese medicine compositions of the present invention are on the impact of diabetes rat glycolated hemoglobin
Table 2 Chinese medicine composition of the present invention is on the impact of diabetes rat HbAlc
*compare with model group, P < 0.05,
*compare with model group, P < 0.01;
#compare with pioglitazone group, P < 0.05,
##compare with pioglitazone group, P < 0.01.
Experimental result show, Chinese medicine composition compared with pioglitazone group in reducing glycolated hemoglobin effect better, between each composition of Chinese medicine composition, there is remarkable synergism.Be embodied in:
1) compared with model control group, the glycolated hemoglobin no difference of science of statistics after the treatment of pioglitazone group, the saccharification hemoglobin content that Chinese medicine is respectively organized all has significant difference;
2) compared with model control group, the saccharification hemoglobin content that Chinese medicine is respectively organized all has significant difference, and wherein Chinese medicine C group and Chinese medicine D group have pole significant difference.
The impact of 4.3 Chinese medicine composition diabetes rat microdose urine proteins of the present invention
Table 3 Chinese medicine composition of the present invention is on the impact of diabetes rat microdose urine protein
*compare with model group, P < 0.05,
*compare with model group, P < 0.01;
#compare with pioglitazone group, P < 0.05,
##compare with pioglitazone group, P < 0.01.
Experimental result shows, and Chinese medicine composition has good synergism affecting in diabetes rat microdose urine protein, and its therapeutic effect is significantly better than positive control drug pioglitazone group.This shows that Chinese medicine composition is delaying to have outstanding treatment advantage in diabetic condition development, minimizing diabetic complication.Be in particular in:
1) compared with model group, the urine micro protein content that pioglitazone group and Chinese medicine are respectively organized all has significant difference, and wherein each group of Chinese medicine has pole significant difference;
2) compared with pioglitazone group, the urine micro protein content of Chinese medicine B, C, D group has significant difference.
embodiment 20 Chinese medicine composition is to the therapeutic effect of spontaneous hypertensive rat blood pressure
1. laboratory animal and experiment grouping
Spontaneous hypertensive rat 60, male, body weight (300 ± 20) g, after adaptability raises one week, is divided into 6 groups at random, often organizes 10.Rat is divided into model control group at random according to blood pressure level, amlodipine group, Chinese medicine composition A group, Chinese medicine composition B group, Chinese medicine composition C group, Chinese medicine composition D group totally 6 groups, often organizes 10.Each group gives following medicine respectively:
Model control group: gavage gives equal-volume normal saline;
Pioglitazone group: gavage gives pioglitazone 2.5mg/kgd;
Chinese medicine A group: it is the Chinese medicine composition composition powders of 1g/kgd that gavage gives crude drug amount prepared by embodiment 1;
Chinese medicine B group: it is the Chinese medicine composition water preparation of 3g/kgd that gavage gives crude drug amount prepared by embodiment 7;
Chinese medicine C group: the crude drug amount that gavage gives embodiment 13 preparation is the Chinese medicine composition tablet of 3g/kgd;
Chinese medicine D group: the crude drug amount that gavage gives embodiment 18 preparation is the agent of 10g/kgd Chinese medicinal composition capsules.
Each group is gastric infusion, once a day, and totally 10 weeks.In experimentation, observe animal diet followed, survival condition and behavioral activity every day, every day measures body weight, according to body weight adjustment drug dose.Put to death animal after 10 weeks, dirty survey left ventricular mass of coring, calculates left room index.
2. experimental technique and experimental result
2.1 hypertension compound recipes are on the impact of spontaneous hypertensive rat blood pressure
Temperature controls at 18 DEG C-22 DEG C, temperature 45%-65%, Indoor Natural light.With tail arterial blood pressure under BP-2006A intelligence non-invasive blood pressure measuring (Beijing Ruan Long company limited provides) measurement rat waking state.Upon administration first week, the 3rd week and the 6th week difference Measure blood pressure, all measure 5 times between 2 hours to 5 hours, get the blood pressure of its average as this sample after gastric infusion.
Table 4 hypertension compound recipe on the impact of spontaneous hypertensive rat blood pressure (
, n=8) and (mmHg)
●p < 0.05 is compared with model group,
● ●p < 0.01 is compared with model group;
▼p < 0.05 is compared with pioglitazone group.
From above result, Chinese medicine composition has good synergism affecting in the hypertension of spontaneous hypertensive rat, and its therapeutic effect is significantly better than positive control drug pioglitazone group.This shows that Chinese medicine composition is delaying to have outstanding treatment advantage in hypertension PD, minimizing hypertension complication.Be in particular in: compared with model group, the hypertension that pioglitazone group and Chinese medicine are respectively organized all has significant difference, and wherein each group of Chinese medicine has pole significant difference.Compared with pioglitazone group, the hypertension reduction effect of Chinese medicine B, C, D group is more excellent.
Claims (4)
1. treat a Chinese medicine composition for Complicating with Hypentersion nephropathy, it is characterized in that being obtained by the raw material of following weight portion: Herba Epimedii 30 parts, the Cortex Eucommiae 15 parts, 15 parts, the Radix Rehmanniae, Rhizoma Polygonati 10 parts, Radix Puerariae 12 parts, Radix Ginseng 7 parts, Fructus Lycii 12 parts, the Radix Astragali 13 parts, Fructus Ligustri Lucidi 14 parts, Radix Platycodonis 10 parts, Radix Ophiopogonis 5 parts, the Rhizoma Pinelliae 11 parts, Rhizoma Chuanxiong 7 parts, Fructus Crataegi 5 parts of Flos Carthami 9 parts.
2. Chinese medicine composition as claimed in claim 1, its feature exists: described Chinese medicine composition is powder, water preparation, tablet or capsule.
3. prepare the method for Chinese medicine composition as claimed in claim 1 for one kind, it is characterized in that comprising the following steps: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, the alcoholic solution that volumetric concentration is 40%-95% is doubly added according to the 4-9 of coarse powder gross weight, reflux, extract, three times, return time is 2-5h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying.
4. the purposes of Chinese medicine composition according to claim 1 in preparation treatment Complicating with Hypentersion nephropathy medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310744647.0A CN103690784B (en) | 2013-12-31 | 2013-12-31 | The Chinese medicine composition for the treatment of Complicating with Hypentersion nephropathy and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310744647.0A CN103690784B (en) | 2013-12-31 | 2013-12-31 | The Chinese medicine composition for the treatment of Complicating with Hypentersion nephropathy and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103690784A CN103690784A (en) | 2014-04-02 |
| CN103690784B true CN103690784B (en) | 2015-09-30 |
Family
ID=50352554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310744647.0A Active CN103690784B (en) | 2013-12-31 | 2013-12-31 | The Chinese medicine composition for the treatment of Complicating with Hypentersion nephropathy and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103690784B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104547613A (en) * | 2014-12-31 | 2015-04-29 | 曾子维 | Application of medicine composition in preparing medicine curing hypertensive nephropathy |
| CN104547498A (en) * | 2014-12-31 | 2015-04-29 | 黎细乐 | New use of traditional Chinese medicine composition |
| CN104784571A (en) * | 2015-04-10 | 2015-07-22 | 冯小平 | Medicinal preparation for treating hypertensive nephropathy |
| CN104771709A (en) * | 2015-04-27 | 2015-07-15 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating diabetes with renal injury and preparation method thereof |
| CN105288410A (en) * | 2015-11-28 | 2016-02-03 | 青岛麦瑞特医药技术有限公司 | Traditional Chinese medicine composition for treating diabetic nephropathy and application of traditional Chinese medicine composition |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101274084A (en) * | 2007-12-18 | 2008-10-01 | 秦庆吉 | Medicament for curing hypertension, hyperlipemia and complication thereof |
| CN102274396B (en) * | 2011-07-25 | 2012-09-26 | 孙新宇 | Traditional Chinese medicine for treating diabetic nephropathy and preparation method thereof |
-
2013
- 2013-12-31 CN CN201310744647.0A patent/CN103690784B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103690784A (en) | 2014-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102988638B (en) | Cyclocarya paliurus blood-lipid and blood-sugar reducing health-care tea and preparation method thereof | |
| CN103053748B (en) | Kudzu vine root fat-reducing sugar-reducing health-care tea and preparation method thereof | |
| CN104435775A (en) | Chinese medicinal health-care spirit and preparation method thereof | |
| CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
| CN103690784B (en) | The Chinese medicine composition for the treatment of Complicating with Hypentersion nephropathy and preparation method | |
| CN103223111B (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof | |
| CN104305205B (en) | A kind of Semen Cuscutae oral liquid improving immunity and preparation method thereof | |
| CN103520621A (en) | Traditional Chinese medicine composition for treating senile cataract and preparation method thereof | |
| CN102885975B (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN104083640B (en) | Traditional Chinese medicinal composition for treating diabetes mellitus and preparation method thereof | |
| CN106924374A (en) | A kind of composition and preparation method thereof and the application in hypoglycemic and/or reducing blood lipid product is prepared | |
| CN105497816A (en) | Traditional Chinese medicine preparation for treating atherosclerosis and preparation method thereof | |
| CN101095793A (en) | Chinese traditional medicine preparations liuweidihuang wine having functions of reinforcing body fluid and nourishing the blood and the kidney | |
| CN103705860B (en) | A kind of Chinese medicine composition for the treatment of infant jaundice and preparation method thereof | |
| CN105343593A (en) | Spica prunellae health oral liquid capable of decreasing blood pressure and blood lipid as well as preparation method of spica prunellae health oral liquid | |
| CN103041255B (en) | Chinese materia medica preparation for curing swollen sore throat and respiratory tract infection of children | |
| CN104825821A (en) | Medicine for treating diabetes and preparation method thereof | |
| CN104922448A (en) | Traditional Chinese medicine composition for treating fundus hemorrhage and application thereof | |
| CN104397282A (en) | Tranquilization and brain tonifying eleutherococcus senticosus healthare tea and preparation method thereof | |
| CN103550505A (en) | Traditional Chinese medicine preparation for treating qi-yin deficiency type diabetes | |
| CN104606570A (en) | Consumptive thirst tea substitute drink suitable for diabetes patients and preparation method of consumptive thirst tea substitute drink | |
| CN105168581A (en) | Application of traditional Chinese medicine composition in preparation of drugs for treating diabetic nephropathies | |
| CN104096073A (en) | Traditional Chinese medicine composition for treating male infertility and preparation method for same | |
| CN112823807A (en) | Donkey-hide gelatin ginseng cream and preparation method thereof | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Yuling Inventor after: Huang Jinhua Inventor before: Wang Yuling Inventor before: Guo Ruiying |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WANG YULING GUO RUIYING TO: WANG YULING HUANG JINHUA |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170601 Address after: 226000, 9 Jiangsu Road, Binjiang fine chemical industry zone, Nantong, Jiangsu, Qidong Patentee after: NANTONG FINC PHARMACEUTICAL CHEMICAL Co.,Ltd. Address before: 266200 Jimo, Qingdao, the Yellow River, No. two, No. Road, building 25, building 182 Patentee before: Wang Xueyan |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Wang Xueyan Document name: Notification of Approving Refund |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 226000, No.78 Jiangsu Road, Binjiang Fine Chemical Industrial Park, Qidong City, Nantong City, Jiangsu Province Patentee after: Nantong Fayink High-tech Material Technology Co.,Ltd. Address before: 226000 9 Jiangsu Road, Binjiang Fine Chemical Industrial Park, Qidong, Nantong, Jiangsu Patentee before: NANTONG FINC PHARMACEUTICAL CHEMICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231207 Address after: 226000 Qidong Binjiang fine chemical industry park, Nantong City, Jiangsu Province Patentee after: Qidong Binhua water supply Co.,Ltd. Address before: 226000, No.78 Jiangsu Road, Binjiang Fine Chemical Industrial Park, Qidong City, Nantong City, Jiangsu Province Patentee before: Nantong Fayink High-tech Material Technology Co.,Ltd. |